Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 5, 2023Journal of Clinical Oncology

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPeter McLaughlinHeidelberg UniversityAGA.J. Grillo-LópezThe University of Texas MD Anderson Cancer CenterBLBrian K. LinkUniversity of Iowa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

McLaughlin et al. (2023) studied this question.

synapsesocial.com/papers/6ab2418ee8d68c1c7b07de61https://doi.org/10.1200/jco.22.02403
View Full Paper
Ask AI
Bookmark
Share